ISR protects the public by managing and intensely supervising persons in the community while providing effective case management, therapeutic interventions and support to reduce

This statewide program provides intensive supervision for the highest-risk individuals. Supervision includes four face-to-face contacts weekly, electronic home monitoring, mandatory work or …

2020年7月17日 · The aim of the AGENT ISR randomised trial is to evaluate angiographic and clinical outcomes in patients with ISR of a previously treated lesion who were treated with …

AGENT is the first and only U.S. coronary drug-coated balloon (DCB), introducing a new treatment option for patients with in-stent restenosis (ISR). AGENT is purposefully designed to …

When a part of the artery with a stent gets blocked or re-narrowed, it’s called in-stent restenosis (ISR). The re-narrowing can be caused by a combination of factors including more plaque …

2024年11月6日 · 近日举行了由全军心血管疾病介入诊疗质控委员会主办、北部战区总医院心内科承办的支架内再狭窄（isr）病例研讨会暨agent药物球囊全国首批试用活动，大会主席是韩雅 …

AGENT ISR 随机试验的目的是评估先前治疗病变的 ISR 患者的血管造影和临床结果，这些患者接受带有新涂层配方的 DCB (Agent) 或标准 DC B (SeQuent Please) 治疗。方法和结果 AGENT …

2024年4月8日 · Patients with in-stent restenosis (ISR) within multiple layers of implanted stents pose a clinical challenge due to limited therapeutic options and high rates of recurrent …

The AGENT™ DCB is used when a patient needs their artery that has previously had a stent implanted, re-opened due to narrowing caused by plaque or scar tissue, the device is inserted …

The aim of the AGENT ISR randomised trial is to evaluate angiographic and clinical outcomes in patients with ISR of a previously treated lesion who were treated with either a DCB with a new …